[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100628244":3},{"organization":4,"armGroups":7,"interventions":32,"overallOfficials":39,"centralContacts":44,"locations":38,"responsibleParty":54,"collaborators":38,"id":56,"slug":57,"hasResults":58,"nctId":59,"briefTitle":60,"officialTitle":61,"acronym":38,"eligibilityCriteria":62,"healthyVolunteers":58,"sex":63,"minAge":64,"maxAge":38,"enrollmentInfo":65,"targetDuration":38,"studyType":68,"phases":69,"briefSummary":72,"conditions":73,"keywords":76,"overallStatus":81,"whyStopped":38,"lastUpdateSubmitDate":82,"lastUpdatePostDateStruct":83,"startDateStruct":86,"completionDateStruct":88,"leadSponsor":90,"locationsCount":38},{"fullName":5,"class":6},"TargED Biopharmaceuticals B.V.","INDUSTRY",[8,14,17,20,23,26,29],{"label":9,"type":10,"description":11,"interventionNames":12},"Dose Level 1","EXPERIMENTAL","TGD001 IV bolus administration",[13],"Drug: TGD001",{"label":15,"type":10,"description":11,"interventionNames":16},"Dose Level 2",[13],{"label":18,"type":10,"description":11,"interventionNames":19},"Dose Level 3",[13],{"label":21,"type":10,"description":11,"interventionNames":22},"Dose Level 4",[13],{"label":24,"type":10,"description":11,"interventionNames":25},"Basket 1",[13],{"label":27,"type":10,"description":11,"interventionNames":28},"Basket 2",[13],{"label":30,"type":10,"description":11,"interventionNames":31},"Basket 3",[13],[33],{"type":34,"name":35,"description":36,"armGroupLabels":37,"otherNames":38},"DRUG","TGD001","IV bolus administration",[24,27,30,9,15,18,21],null,[40],{"name":41,"affiliation":42,"role":43},"Marielle Klein Hesselink, MD","TargED","STUDY_DIRECTOR",[45,50],{"name":46,"role":47,"phone":48,"phoneExt":38,"email":49},"Melinda Snyder","CONTACT","1 617 233 4057","melinda.snyder@targedbio.com",{"name":51,"role":47,"phone":52,"phoneExt":38,"email":53},"Barbara van den Aarsen","31620161487","barbara.van.den.aarsen@Targedbio.com",{"type":55,"investigatorFullName":38,"investigatorTitle":38,"investigatorAffiliation":38,"oldNameTitle":38,"oldOrganization":38},"SPONSOR","100628244","phase-1-tgd001-treatment-in-thrombotic-microangiopathies-100628244",false,"NCT07459114","TGD001 Treatment in Thrombotic Microangiopathies","An Adaptive Dose Escalation and Expansion Basket Trial to Explore the Safety, Pharmacology, and Clinical Activity of TGD001 in Immune-Mediated Thrombotic Thrombocytopenic Purpura (iTTP) and Other Thrombotic Microangiopathies","Key Inclusion Criteria:\n\n* 18 years old or older\n* Willing to sign an informed consent form\n* Willing to refrain from sexual intercourse or must use a contraceptive method that is highly effective for 90 days after the last dose of TGD001\n* Symptomatic acute TMA episode\n* Accessible to follow-up\n\nKey Exclusion Criteria:\n\n* Diagnosis other than TMA, which could account for the findings of thrombocytopenia and hemolytic anemia\n* Diagnosis of Shiga-toxin induced HUS\n* Known bone marrow\u002Fgraft failure\n* Diagnosis of ongoing severe, uncontrolled Graft versus Host Disease\n* Received therapeutic plasma exchange (PEX) within 7 days prior to screening\n* Use of an anticoagulant and\u002For thrombolytics\n* Active internal bleeding\n* Any major bleeding episode within the past 30 days, or diagnosis of chronic bleeding conditions\n* Known gastrointestinal ulcer\n* Severe, uncontrolled hypertension, renal impairment requiring dialysis, or liver impairment, or active infection indicated by sepsis\n* Life expectancy less than 3 months independent of TMA disorder\n* Pregnant or breastfeeding","ALL","18 Years",{"count":66,"type":67},70,"ESTIMATED","INTERVENTIONAL",[70,71],"PHASE1","PHASE2","This is a Phase 1\u002F2, prospective, adaptive design trial of TGD001 in participants with suspicion or clinical diagnosis of acute immune thrombotic thrombocytopenic purpura (iTTP) episodes and participants with suspicion or clinical diagnosis of an acute Thrombotic Microangiopathy (TMA) episode. The trial is an open-label, dose escalation and expansion basket trial.",[74,75],"Thrombotic Microangiopathies","ITP Immune-Mediated Thrombocytopenia",[77,78,74,79,80,35],"iTTP","TMA","immune-mediated thrombotic thrombocytic purplura","thrombotic microangiopathy","NOT_YET_RECRUITING","2026-03-06",{"date":84,"type":85},"2026-03-09","ACTUAL",{"date":87,"type":67},"2026-05-31",{"date":89,"type":67},"2028-08-30",{"name":5,"class":6}]